annb0t
Top 20
Mesoblast Ltd (NASDAQ: MESO) rallied after the FDA agreed to review the company's lead drug candidate, remestemcel-L, on a priority basis, more than two years after first rejecting it. The drug is an investigational therapy that comprises culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. The product is under priority review for children suffering from steroid-refractory acute graft versus host disease (SR-aGVHD). The FDA said it considered Mesoblast's...
>>> Read more: Mesoblast's Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids
>>> Read more: Mesoblast's Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids
